PYC Therapeutics (ASX:PYC) Announces Q1 2025 Shareholder Update
PYC Therapeutics (ASX:PYC) extends cash runway to over $200m and advances polycystic kidney disease program in Q1 2025.
PYC Therapeutics (ASX:PYC) extends cash runway to over $200m and advances polycystic kidney disease program in Q1 2025.
Atomo Diagnostics Limited (ASX:AT1) completes a $3.1 million capital raise and announces a board restructure to enhance operational efficiency and drive growth.
PWR (ASX:PWH) announces the temporary leave of its Managing Director and the appointment of Matthew Bryson as Acting CEO.
Dreadnought Resources Ltd (ASX:DRE) closes its Share Purchase Plan, raising $1.73M with strong shareholder support.
WiseTech Global (ASX:WTC) updates executive chair agreement and shares progress on CEO succession planning.
360 Capital Group (ASX:TGP) announces an off-market buy-back of up to 15.4% of its securities at $0.65 per security.
Waypoint REIT (ASX:WPR) announces a $50 million buyback and expansion of OTR conversions with Viva Energy to boost shareholder value.
Platinum Capital Limited (ASX:PMC) recommends its restructuring scheme, prioritising it over a competing acquisition proposal.
Dropsuite Limited (ASX:DSE) has been declared to have unacceptable circumstances by the Takeovers Panel due to major shareholder Topline’s non-compliance.
Bigtincan Holdings Limited (ASX:BTH) shareholders approve an acquisition scheme managed by a Vector Capital fund, moving towards the takeover.